vs
合众银行（FSBC）与IOVANCE BIOTHERAPEUTICS, INC.（IOVA）财务数据对比。点击上方公司名可切换其他公司
IOVANCE BIOTHERAPEUTICS, INC.的季度营收约是合众银行的1.9倍（$86.8M vs $45.1M），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs 21.3%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
FSBC vs IOVA — 直观对比
营收规模更大
IOVA
是对方的1.9倍
$45.1M
两年增速更快
IOVA
近两年复合增速
21.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $86.8M |
| 净利润 | $18.6M | — |
| 毛利率 | — | 67.4% |
| 营业利润率 | — | -84.7% |
| 净利率 | 41.3% | — |
| 营收同比 | — | 17.7% |
| 净利润同比 | 42.0% | — |
| 每股收益（稀释后） | $0.87 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCIOVA
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $86.8M | ||
| Q3 25 | $41.3M | $67.5M | ||
| Q2 25 | $38.3M | $60.0M | ||
| Q1 25 | $35.3M | $49.3M | ||
| Q4 24 | $35.2M | $73.7M | ||
| Q3 24 | $31.8M | $58.6M | ||
| Q2 24 | $30.7M | $31.1M |
净利润FSBCIOVA
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | — | ||
| Q3 25 | $16.3M | $-91.3M | ||
| Q2 25 | $14.5M | $-111.7M | ||
| Q1 25 | $13.1M | $-116.2M | ||
| Q4 24 | $13.3M | — | ||
| Q3 24 | $10.9M | $-83.5M | ||
| Q2 24 | $10.8M | $-97.1M |
毛利率FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
营业利润率FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | -84.7% | ||
| Q3 25 | 53.8% | -140.7% | ||
| Q2 25 | 52.4% | -189.8% | ||
| Q1 25 | 52.0% | -245.8% | ||
| Q4 24 | 55.1% | -117.5% | ||
| Q3 24 | 48.0% | -152.1% | ||
| Q2 24 | 49.4% | -327.6% |
净利率FSBCIOVA
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | — | ||
| Q3 25 | 39.6% | -135.3% | ||
| Q2 25 | 37.9% | -186.2% | ||
| Q1 25 | 37.1% | -235.5% | ||
| Q4 24 | 37.9% | — | ||
| Q3 24 | 34.4% | -142.7% | ||
| Q2 24 | 35.2% | -312.2% |
每股收益（稀释后）FSBCIOVA
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | — | ||
| Q3 25 | $0.77 | — | ||
| Q2 25 | $0.68 | $-0.33 | ||
| Q1 25 | $0.62 | $-0.36 | ||
| Q4 24 | $0.61 | $-0.24 | ||
| Q3 24 | $0.52 | $-0.28 | ||
| Q2 24 | $0.51 | $-0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $297.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $458.5M | $698.6M |
| 总资产 | $5.0B | $913.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FSBCIOVA
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
股东权益FSBCIOVA
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $698.6M | ||
| Q3 25 | $431.3M | $702.3M | ||
| Q2 25 | $416.7M | $698.5M | ||
| Q1 25 | $406.5M | $767.9M | ||
| Q4 24 | $396.6M | $710.4M | ||
| Q3 24 | $389.9M | $773.5M | ||
| Q2 24 | $380.5M | $768.5M |
总资产FSBCIOVA
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $913.2M | ||
| Q3 25 | $4.6B | $904.9M | ||
| Q2 25 | $4.4B | $907.4M | ||
| Q1 25 | $4.2B | $966.7M | ||
| Q4 24 | $4.1B | $910.4M | ||
| Q3 24 | $3.9B | $991.1M | ||
| Q2 24 | $3.6B | $964.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-61.9M |
| 自由现金流率自由现金流/营收 | — | -71.3% |
| 资本支出强度资本支出/营收 | — | 10.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-336.2M |
8季度趋势，按日历期对齐
经营现金流FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $-52.6M | ||
| Q3 25 | $18.8M | $-78.7M | ||
| Q2 25 | $17.8M | $-67.4M | ||
| Q1 25 | $15.5M | $-103.7M | ||
| Q4 24 | $51.8M | $-73.3M | ||
| Q3 24 | $17.5M | $-59.0M | ||
| Q2 24 | $16.0M | $-98.4M |
自由现金流FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | $-61.9M | ||
| Q3 25 | $18.6M | $-89.5M | ||
| Q2 25 | $17.5M | $-74.9M | ||
| Q1 25 | $15.4M | $-109.9M | ||
| Q4 24 | $51.2M | $-77.5M | ||
| Q3 24 | $17.3M | $-61.3M | ||
| Q2 24 | $15.8M | $-98.9M |
自由现金流率FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | -71.3% | ||
| Q3 25 | 45.0% | -132.7% | ||
| Q2 25 | 45.8% | -124.9% | ||
| Q1 25 | 43.5% | -222.8% | ||
| Q4 24 | 145.5% | -105.1% | ||
| Q3 24 | 54.5% | -104.6% | ||
| Q2 24 | 51.6% | -317.9% |
资本支出强度FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 10.7% | ||
| Q3 25 | 0.5% | 16.1% | ||
| Q2 25 | 0.6% | 12.4% | ||
| Q1 25 | 0.3% | 12.6% | ||
| Q4 24 | 1.8% | 5.7% | ||
| Q3 24 | 0.7% | 3.9% | ||
| Q2 24 | 0.7% | 1.4% |
现金转化率FSBCIOVA
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
